drug
dexamethasone
Marketedupdated 3mo agoby Fera Pharmaceuticals LLC
Approvedcommunity read0 votes
indications
investigational
Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma
all catalysts(10)
phase 0 trial completion · 1
phase 2 completion · 7
Apr 25, 2026
phase 2 completion
Nizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 25, 2026
phase 2 completion
Assiut University — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 27, 2026
phase 2 completion
BC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 28, 2026
phase 2 completion
West China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Buddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Dalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)
dexamethasone
→
phase 2 initiation · 1
Trials studying dexamethasone
- phase2Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
- phase3Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- phase2Lazarus: IT Therapy for ICANS
- phase2Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- phase2AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- phase2A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 3, 2026
43 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 18, 2037formulationUS 10537585
- Dec 18, 2037formulationUS 11304961
FDA exclusivities (1)
- Oct 3, 2026ODE-271Orphan Drug (7y)43d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 40m ago
Found something off?
comments(0)
5-min edit window · permanent after that